• Genomic testing may help separate men who need stronger prostate cancer treatment from those who do not
• Researchers looked at how the Decipher test lined up with outcomes in high-risk prostate cancer
• Abiraterone showed major benefit in some patients, but not everyone needs that extra step
• Lower scores may point to less aggressive disease, while higher scores may signal a bigger threat
• Experts say the goal is smarter treatment with fewer side effects and less wasted therapy
A new prostate cancer test could make treatment a lot less of a guessing game. Instead of giving the same aggressive plan to every high-risk patient, doctors may soon have a better way to spot who truly needs it and who might be fine with less.
Researchers at University College London studied a tissue-based genomic test called Decipher and used it to see which men with high-risk prostate cancer were most likely to benefit from stronger therapy. The idea is simple but powerful: if a cancer is biologically more dangerous, it should be treated harder, but if it is less likely to spread, piling on extra medicine may only add trouble.
The focus of the analysis was abiraterone, a hormone therapy that has already shown it can cut the risk of death in men with high-risk, localized prostate cancer. That sounds like an obvious win, but the reality is more complicated because prostate cancer is not one disease with one behavior.
Some tumors are more stubborn, more active, and more likely to spread. Others move slower and may not need the same level of treatment, which is where a genomic test can help cut through the noise.
The research was presented at the European Society for Medical Oncology Congress in Madrid. It drew on a huge real-world dataset of more than 27,000 patients, along with 401 men who had non-metastatic prostate cancer and had been enrolled in the STAMPEDE abiraterone trial.
The pattern that emerged was pretty clear. Higher Decipher scores lined up with worse outcomes, which means those cancers were more likely to behave aggressively and may be better candidates for added treatment.
On the flip side, lower Decipher scores suggested a lower risk of spread. That matters because men with less aggressive disease might be spared treatment that brings fatigue, other side effects, and a hit to quality of life without offering much payoff.
Lead researcher Dr. Sarah Howlett said that keeping the disease from spreading is critical for men with very high-risk prostate cancer. She also stressed that understanding who benefits most from added treatment can make a real difference, especially when the stakes are this high.
The appeal of this approach is obvious to anyone who has watched cancer care evolve. The old one-size-fits-all model often pushes too hard in some cases and not hard enough in others, and genomic testing gives doctors one more tool to avoid that trap.
Experts said the findings support the growing move toward personalized medicine. Rather than guessing which men should get abiraterone on top of standard treatment, the test could help show who is most likely to gain from the extra firepower.
That does not mean the test is ready to become a universal rule overnight. Howlett noted that more validation is still needed in other datasets before it is used routinely to make treatment decisions.
Still, the signal is strong enough to turn heads. Seeing the same pattern in both a large real-world group and a randomized clinical trial gives the result more weight than if it had come from just one small study.
Another expert, Elai Davicioni of Veracyte, said the evidence gives physicians a stronger reason to use Decipher before making decisions that can affect both cancer outcomes and patients’ quality of life. That balance matters, because the point is not just living longer, but living better while treatment does its job.
Fox News senior medical analyst Dr. Marc Siegel said prostate cancer is not a one-size-fits-all disease and that medicine is increasingly moving in the right direction. He pointed out that localized prostate cancer can carry mutations that help predict how aggressive it may become and whether targeted therapies could work better.
Hormone therapies can be valuable, but they are not gentle for everyone. Siegel noted that these drugs can bring significant side effects, including fatigue, and that stronger treatment does not always mean better treatment if the cancer is unlikely to need it in the first place.
The larger message is hard to miss. Prostate cancer care is shifting away from broad strokes and toward sharper, more tailored decisions, where the biology of the tumor helps guide the plan instead of just the diagnosis label.
That shift could matter for a lot of men. Prostate cancer remains one of the most common cancers in men, and the search for better ways to match treatment intensity with real risk is only getting more important as doctors look for smarter ways to protect both survival and everyday life.
